A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), α-tocopherol was ineffective in the DATATOP study

This publication has 10 references indexed in Scilit:

• Antiaging Compounds: (‐)Deprenyl (Selegiline) and (‐)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(‐)BPAP], a Selective Highly Potent Enhancer of the Impulse Propagation Mediated Release of Catecholamines and Serotonin in the Brain
  CNS Drug Reviews, 2001
• Structure–activity studies leading to (−)1-(Benzofuran-2-yl)-2-propylaminopentane, ((−)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of Catecholamines and Serotonin in the brain
  Bioorganic & Medicinal Chemistry, 2001
• (−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
  British Journal of Pharmacology, 1999
• (‐)Deprenyl (Selegiline), a Catecholaminergic Activity Enhancer (CAE) Substance Acting in the Brain
  Basic & Clinical Pharmacology & Toxicology, 1998
• Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain
  Life Sciences, 1996
• (−)Deprenyl and (−)1-phenyl-2-propylaminopentane, [(−) PPAP] act primarily as potent stimulants of action potential — transmitter release coupling in the catecholaminergic neurons
  Life Sciences, 1996
• Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic (-)deprenyl (selegiline) medication
  Life Sciences, 1995
• Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
  New England Journal of Medicine, 1993
• Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
  New England Journal of Medicine, 1989
• The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
  Science, 1989